PARP inhibition by olaparib alleviates chronic asthma‐associated remodeling features via modulating inflammasome signaling in mice
Sign Up to like & getrecommendations! Published in 2019 at "IUBMB Life"
DOI: 10.1002/iub.2048
Abstract: Despite the reported role of poly(ADP‐ribose) polymerase (PARP) in asthma inflammation, its contribution during remodeling is not clearly known. The main aim of the current investigation was to examine the potential of olaparib, a pharmacological… read more here.
Keywords: olaparib; via modulating; inflammasome signaling; chronic asthma ... See more keywords
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05320-4
Abstract: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in… read more here.
Keywords: real world; sharing real; olaparib toxicities; management ... See more keywords
In the literature: February 2021
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100061
Abstract: BRCA1 is a tumor-suppressor gene that encodes proteins involved in the repair of DNA double-strand breaks by way of the homologous recombination repair pathway. BRCA1 mutations occur in approximately 5% of breast cancer (BC) patients.… read more here.
Keywords: literature february; anti csf1r; february 2021; treatment ... See more keywords
Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Sign Up to like & getrecommendations! Published in 2020 at "European urology"
DOI: 10.1016/j.eururo.2020.09.024
Abstract: The PROfound trial evaluated the PARP inhibitor olaparib in metastatic castration-resistant prostate cancers harboring alterations in BRCA1/2 and ATM (cohort A) and in 12 other homologous recombination repair genes (cohort B). Olaparib led to more… read more here.
Keywords: olaparib; cohort; metastatic castration; castration resistant ... See more keywords
In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib
Sign Up to like & getrecommendations! Published in 2017 at "Xenobiotica"
DOI: 10.1080/00498254.2016.1241449
Abstract: Abstract 1. In vitro assessments were conducted to examine interactions between olaparib (a potent oral inhibitor of poly[ADP-ribose] polymerase) and drug transporters. 2. Olaparib showed inhibition of the hepatic drug uptake transporters OATP1B1 (IC50 values of 20.3 μM… read more here.
Keywords: limited inhibition; inhibition; drug; olaparib ... See more keywords
Olaparib, a clinically used poly(ADP-ribose) polymerase inhibitor protects against oxidant-induced cardiac myocyte death in vitro and improves cardiac contractility during early phase after heart transplantation in a rat model in vivo.
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.13983
Abstract: Background and purpose Olaparib, rucaparib and niraparib, potent inhibitors of poly(ADP-ribose) polymerase (PARP) have recently been approved for human use for oncological indications. Considering the previously demonstrated role of PARP in various forms of acute… read more here.
Keywords: heart; olaparib; model; transplantation ... See more keywords
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.14929
Abstract: Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase… read more here.
Keywords: fadu cells; fadu; parp inhibitor; olaparib ... See more keywords
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2409
Abstract: Purpose: Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer… read more here.
Keywords: olaparib; cancer; sensitivity; colorectal cancer ... See more keywords
Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-21-0604
Abstract: PARP inhibition represents the dawn of precision medicine for treating prostate cancer. Despite this advance, questions remain regarding the use of PARP inhibitors (PARPi's) for the treatment of this disease, including 1) how specifically do… read more here.
Keywords: checkpoint; olaparib; dna; treatment ... See more keywords
Abstract 3582: Differentiation of niraparib and olaparib brain penetration in a mouse brain metastatic tumor model
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3582
Abstract: Purpose: There remains an unmet need to provide effective treatment therapy for patients with primary and metastatic brain tumors; lack of drug penetration across the blood brain barrier (BBB) is a key factor. Synthetic lethality… read more here.
Keywords: olaparib; control; brain; brain penetration ... See more keywords
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct145
Abstract: Background: Poly-ADP ribose polymerase inhibitors (PARPi) work by impairing DNA damage repair and have demonstrated activity in patients with BRCAmt breast cancer. Their mechanism of action leads to high mutational burden and increased neoantigens suggesting… read more here.
Keywords: olaparib; advanced breast; trial; breast cancer ... See more keywords